The FDA is aware that Omnicell (OMCL) has issued a letter to affected customers recommending certain syringe labels used with the i.v.STATION automated compounding system be removed from where they are used or sold. Affected devices: IVSTATION SYRINGE sterile label (40MMX40MM) – part number 258920028; IVSTATION SYRINGE sterile label (20MMX40MM) – part number 258920029. On April 10, Omnicell sent all affected customers a letter recommending the following actions: Do not use labels affected by this recall. If you or your staff locate any affected labels, immediately segregate and contact Omnicell Technical Support. Omnicell received a report of mislabeling that could affect sterile syringe labels produced using i.v.STATION. Omnicell identified inconsistent label detection behavior across i.v.STATION printers when using the sterile labels affected by this recall. Inconsistent label detection could result in unlabeled or mislabeled syringe preparations after compounding completion where the above identified sterile labels are utilized. As of April 10, Omnicell has reported no serious injuries or deaths associated with this issue.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell Earnings Call Highlights Profits and Momentum
- Omnicell price target raised to $55 from $53 at Craig-Hallum
- Omnicell appoints Rick Couldry as SVP, chief pharmacy and clinical officer
- Omnicell price target raised to $70 from $60 at KeyBanc
- Analyst Reiterates Buy on Omnicell, Citing Once-in-a-Decade Product Cycle Momentum and Margin Strength; Price Target Maintained at $70
